AZ, MSD's Koselugo bags US approval
The drug is the first in the world to be approved to treat this rare and debilitating genetic condition
14th April 2020
Latest news
Lilly to test Olumiant, LY3127804 against COVID-19
The RA drug Olumiant will be assessed in patients hospitalised with the virus
14th April 2020
Avacta and Cytiva team up for COVID-19
The firms will develop and manufacture an Affimer-based point-of-care rapid test for screening large populations for COVID-19 infection
9th April 2020
Tiziana develops delivery tech for COVID-19 treatment
This technology enables direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs
9th April 2020
Circassia pulls plug on AZ agreement
Circassia will shed its debt to AstraZeneca under the move
9th April 2020
FDA, EMA accept Opdivo-Yervoy filings in lung cancer
The filing is based on data from the CheckMate-9LA trial, which showed a benefit in overall survival
9th April 2020
Bayer wins EU approval for Eylea syringe
The syringe provides a new streamlined method to administer Eylea
9th April 2020
Oxford Biomedica joins consortium for promising COVID-19 vaccine
According the firm, the vaccine candidate is one of the most promising in development
8th April 2020
Expanded EU approval for Takeda's Alunbrig
The expanded indication provides the around 10,000 people living with ALK+ NSCLC in Europe an additional first-line treatment option
8th April 2020
Alynlam completes EU, US filings for lumasiran
If approved, lumasiran would be the first approved therapeutic treatment option for primary hyperoxaluria type 1
8th April 2020
Vertex Foundation donates funds to support COVID-19 efforts
The move falls under a $5-million global programme to support the COVID-19 pandemic response around the world
8th April 2020
Cancer Research UK cuts fundings grants amid pandemic uncertainty
The cuts equate to £44 million, driven by a loss in fundraising income
7th April 2020
GSK links with Vir Biotechnology to find coronavirus solutions
GSK has bought a $250 million stake in the firm
7th April 2020
Firms form alliance to work on COVID-19 therapy
The alliance will immediately start work on the development of an unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine
7th April 2020
Imophoron develops COVID-19 vaccine candidates
Preclinical testing expected "within weeks"
7th April 2020
